icometrix

The field of #Alzheimer's treatment is rapidly changing, is your clinical practice ready? 🧠 Join us at #AAIC to discover icobrain aria, the latest development of icometrix, using our deep learning algorithms to detect ARIA-E and ARIA-H. Find our team at booth #738. 💬 We will be there to answer all your questions and discuss how we can support your clinical practice in the treatment of people living with Alzheimer's disease. See you there! 👋 #AAIC24 #AAIC2024 #icobrain #ad #alzheimersdisease #neurology #radiology #neuroradiology #healthcare #ai

For a few years now, our slogan at icometrix has been #BrainHealthMatters 🧠 Clever wordplay aside, this #WorldBrainDay, we want to talk about the growing burden of neurological disorders and the crucial role #medicaltechnology can play 👇 The increasing rate at which neurological disorders are occurring is alarming, affecting millions of lives and putting pressure on healthcare systems and professionals worldwide. Medical technology like #icobrain has proven to help reduce the burden on clinicians and support them in their jobs. However, a clear financial support system is essential, much like the CPT reimbursement code for icobrain in the US 🇺🇸 (read more via the link in comments). Introduced 8 months ago, these CPT codes for icobrain are already making an impact in the US 🇺🇸 #radiology field, enabling clinical sites to access state-of-the-art #icobrain technology that was previously out of reach, or allowing hospitals to roll out the software for all their patients instead of just a subset. The result? More patients receiving the world-class care they deserve. The US reimbursement system, while complex, can serve as an example for the #EU, #Australia, #Canada, #Japan, and others. A unified European legislation could pave the way for more streamlined access to these vital technologies. By working together and advocating for these necessary changes, we can make a real difference in the lives of people living with neurological disorders. Let's continue to strive for a future where brain health is a priority for all. Together, we can make a difference. 🤝 Please repost so we can reach policy makers 🤝 or share your thoughts below! #reimbursement #HealthPolicy #digitalhealth #neurology #worldbrainday #icobrain European Academy of Neurology American Academy of Neurology World Federation Of Neurology

Attending AAIC2024 in Philadelphia? Don’t miss the chance to connect with this icometrix dreamteam: Wim Van Hecke, Rebecca Bartz, and Kathy Hampton! 🧠 With the news of #donanemab (#kisunla) receiving #FDA clearance, the time is now to come and talk to use about FDA pending icobrain aria, our #AI based software designed for the Automated Detection and Quantification of Amyloid-related Imaging Abnormalities. 📽 Want to see a short demo of icobrain aria by our CTO Dirk Smeets? Check the link in comments! Join us for an engaging discussion at #AAIC2024 booth #738! See you there! 👋

📊 Evaluating the efficacy and safety of disease-modifying treatments in real-world clinical practice is essential to understand how clinical trial results translate to broader patient populations. This recent paper on the real-world assessment of dimethyl fumarate showcases how icometrix can support these critical studies with #icobrain. 📰 Check the link in the comments to dive into the full article! In collaboration with: 👉 Stephen Krieger Myassar Zarif Barbara Bumstead Marijean Buhse Olivia Kaczmarek Jared Srinivasan Nuno Miguel Pedrosa de Barros Diana Sima Annemie Ribbens Wim Van Hecke James Lewin Jason Mendoza, Ph.D. Mark Gudesblatt

🎥 #Donanemab receives FDA clearance  🚀 But what now? What will be the impact of the increased number of safety scans and the difficulty of diagnosing ARIA? Most of you will probably already have read the news about the FDA approval of Eli Lilly and Company’s #Kisunla (#Donanemab) for early symptomatic stages of Alzheimer’s disease. Clinical trials have shown a significant 35% reduction in cognitive decline over 1.5 years with this innovative therapy. However, the treatment is associated with an increased rate of Amyloid-Related Imaging Abnormalities (#ARIA), which presents both challenges and opportunities for improved diagnostic and therapy strategies.  🎥 In this video, our CTO Dirk Smeets explains these challenges and presents #icobrain aria, the only clinically validated tool for monitoring ARIA-E and ARIA-H. icobrain aria was developed using actual ARIA data and in its validation paper (Sima et al. 2024) icobrain aria showed a significantly improved radiological reader performance for both ARIA-E and ARIA-H 📊 Importantly, icobrain aria is reimbursed once regulatory clearance is obtained, thanks to the CPT codes for icobrain, ensuring that this technology is accessible to those who need it. How do you think AI can further revolutionize Alzheimer’s treatment? Share your thoughts below! 💬 For more info on icobrain aria, check out https://lnkd.in/en_nnafe and leave your email behind to! #neurology #radiology #neuroimaging #AI #healthcareinnovation #alzheimersdisease #alzheimer #dementia #neuroradiology #icometrix #mri

Exciting news today! After Aduhelm and Leqembi, Eli Lilly and Company's Kisunla (donanemab) is approved for the treatment of early symptomatic #Alzheimer's Disease. The phase III trial demonstrated it slowed cognitive and functional decline by up to 35% compared to placebo after 1.5 years. Compared to Leqembi, Kisunla has a lower frequency of infusion (monthly instead of biweekly) and is the only medication with evidence to support stopping treatment when amyloid plaques are removed. At the downside, the rates of Amyloid related imaging abnormalities (#ARIA), the most common side effect, are higher. As icometrix, we are committed to support the management of #ARIA with #AI, to reduce the possible negative impact of #ARIA. With synergies of innovative treatments and technology, we improve the lives of many patients.

EAN is coming to an end! It was amazing to meet our partners and witness the rapidly changing landscape of neurology 🧠. We enjoyed insightful talks on #multiplesclerosis, #dementia, #NMO, #MOGAD, #parkinson and other neurological diseases and we are happy to contribute our own scientific work on the #MS topographical model and the relationship between NfL and imaging biomarkers in the #TREMEND trial. It's not too late to meet us. If you are still in Helsinki, reach out to An Tanghe and Lars Costers to plan a meeting. 🇫🇮

Join us in Helsinki for two #EAN poster presentions 🚰🩸where we'll present our latest work featuring Stephen Krieger and Michael Barnett on how lesion parenchymal fraction supports the topographical model in MS🚰 and recent work with Tobias Sejbæk, Zsolt Illes, Ronald Antulov, Jason Mendoza, Ph.D. and James Lewin on the associations between NfL levels and imaging biomarkers on #dimethylfumarate🩸 Curious? Join us Saturday at 13.15 - 13.21 in Poster Session 1 Can't make it? Reach out to Lars Costers or An Tanghe to plan a meeting during #EAN2024 👋

Join us in Helsinki for two #EAN poster presentions 🚰🩸where we'll present our latest work featuring Stephen Krieger and Michael Barnett on how lesion parenchymal fraction supports the topographical model in MS🚰 and recent work with Tobias Sejbæk, Zsolt Illes, Ronald Antulov, Jason Mendoza, Ph.D. and James Lewin on the associations between NfL levels and imaging biomarkers on #dimethylfumarate🩸 Curious? Join us Saturday at 13.15 - 13.21 in Poster Session 1 Can't make it? Reach out to Lars Costers or An Tanghe to plan a meeting during #EAN2024 👋

Neurologists are overwhelmed with information/administration and they need to make life-changing clinical decisions for people with brain disorders. A recent MedScape survey indicated that 45% of neurologists experience burnout symptoms. At icometrix, we're passionate about helping reduce the burden for radiologists and neurologists and provide clinically relevant data at their fingertips. Hence, we are launching the brand new #icompanion HCP portal, a user-friendly dashboard that integrates #icobrain imaging biomarkers with patient-reported outcomes. With one click from within your electronic medical record, HCP's can access key patient (imaging) data, track symptom progression, and access the patients’ visit preparation. In the video below, our Director of Clinical Applications, Lars Costers, explains the HCP portal briefly. Many hospitals worldwide have adopted the #icompanion HCP portal, impacting workflows, access to relevant data, clinical decision-making, and patient care. Please contact us if you are interested in learning more about how this new HCP portal can transform your clinical workflow. Leave a comment below or email us at info@icometrix.com! #neurology #healthcareinnovation #digitalhealthcare #ai #braindisease #healthcare #neuroradiology #radiology #precisionmedicine #icometrix